Spectrum Pharmaceuticals Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$18.2M
Doctors Paid
2,905
Transactions
9,794
2024 Total
$434,435
Payment Breakdown by Category
Research$15.8M (86.9%)
Royalty/License$967,007 (5.3%)
Consulting$511,231 (2.8%)
Food & Beverage$158,660 (0.9%)
Travel$147,219 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.8M | 2,856 | 86.9% |
| Royalty or License | $967,007 | 10 | 5.3% |
| Consulting Fee | $511,231 | 181 | 2.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $414,607 | 20 | 2.3% |
| Food and Beverage | $158,660 | 6,121 | 0.9% |
| Travel and Lodging | $147,219 | 454 | 0.8% |
| Honoraria | $82,425 | 27 | 0.5% |
| Education | $79,370 | 120 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $12,400 | 2 | 0.1% |
| Grant | $750.00 | 2 | 0.0% |
| Gift | $345.00 | 1 | 0.0% |
Payments by Type
Research
$15.8M
2,856 transactions
General
$2.4M
6,938 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| SPI-GCF-301 | $3.9M | 4 | 915 |
| SPI-POZ-202 | $2.6M | 0 | 499 |
| SPI-GCF-302 | $2.3M | 2 | 565 |
| IIS-POZ-001 | $986,900 | 0 | 1 |
| A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) | $960,273 | 0 | 98 |
| SPI-POZ-201 | $884,618 | 1 | 253 |
| SPI-FOL-101 | $695,741 | 0 | 48 |
| SPI-QAP-306 | $633,974 | 3 | 211 |
| Phase II study of poziotinib in EGFR exon 20 mutant advanced non-small cell lung cancer (NSCLC) | $486,886 | 0 | 6 |
| SPI-FOL-14-201 | $314,736 | 0 | 47 |
| SPI-GCF-104 | $310,084 | 0 | 22 |
| A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients with Solid Tumors or Lymphomas and Treated with Myelosuppressive Chemotherapy | $172,645 | 0 | 13 |
| FOL-14-201 | $165,623 | 0 | 1 |
| A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation | $159,600 | 0 | 3 |
| A Phase II Study of Poziotinib in EGFR or HER2 Exon 20Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) | $138,298 | 0 | 1 |
| Open Label Phase One Study to Evaluate Duration of Severe Neutropenia After the Same Day Dosing Time Schedules of Elfapegrastim Administration in Patients with Breast Cancer Receiving Docetaxel and Cyclophosphamide | $124,713 | 0 | 15 |
| SPI-EOQ-13-305 | $109,808 | 3 | 50 |
| IIS-ZEV-001 | $85,500 | 0 | 1 |
| SPI-BEL-105 | $83,130 | 0 | 8 |
| SPI-QAP-305 | $74,053 | 1 | 33 |
| IIS-MEL-003 | $50,691 | 0 | 2 |
| IIS-MEL-002 | $50,050 | 0 | 1 |
| T2012-002 MARQIBO | $44,750 | 0 | 1 |
| Propel 008 | $36,154 | 0 | 1 |
| SPI-POZ-101 | $35,632 | 1 | 12 |
| IIS-P-BelMel-001 | $35,000 | 0 | 1 |
| An Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients who have had Previous Exposure to Poziotinib | $31,960 | 0 | 6 |
| Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20 Non-Hodgkin's Lymphoma | $30,000 | 0 | 1 |
| Melphalan - General | $29,985 | 0 | 1 |
| 2016-0211 | $22,737 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 117
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Donald Miller, Md, MD | Hematology & Oncology | Louisville, KY | $10.47 | $0 |
| Paul Dekker, Md, MD | Hematology & Oncology | Hartford, CT | $10.47 | $0 |
| Zaki Samman, Md, MD | Medical Oncology | Fort Smith, AR | $10.44 | $0 |
| Diane Wilder, M.d, M.D | Hematology & Oncology | Little Rock, AR | $10.42 | $0 |
| Stephen Lemon, Md, MD | Medical Oncology | Silverdale, WA | $10.33 | $0 |
About Spectrum Pharmaceuticals Inc.
Spectrum Pharmaceuticals Inc. has made $18.2M in payments to 2,905 healthcare providers, recorded across 9,794 transactions in the CMS Open Payments database. In 2024, the company paid $434,435. The top product by payment volume is Folotyn ($1.4M).
Payments were distributed across 83 medical specialties. The top specialty by payment amount is Hematology & Oncology ($471,762 to 1,141 doctors).
Payment categories include: Food & Beverage ($158,660), Consulting ($511,231), Research ($15.8M), Travel & Lodging ($147,219), Royalties ($967,007).
Spectrum Pharmaceuticals Inc. is associated with 6 products in the CMS Open Payments database, including Folotyn, ROLVEDON, and Evomela.